Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The treatment goal of ulcerative colitis (UC) has been changed to achieve endoscopic remission (ER). However, there is insufficient clinical evidence to determine whether a step-up treatment should be performed to achieve ER in clinical remission (CR) without ER, and there are inadequate data on the need to consider the distribution and severity of residual inflammation. This retrospective study aimed to evaluate the prognostic significance of the distribution and severity of residual inflammation in UC patients in CR. Methods: A total of 131 UC patients in CR who underwent endoscopic evaluation for more than three times between January 2000 and December 2018 were reviewed. The patients were allocated by the endoscopic healing state and the distribution of inflammation to ER (n=31, 23.7%), residual nonrectal inflammation with patchy distribution (NRI) (n=17, 13.0%) or residual rectal involvement with continuous or patchy distribution (RI) (n=83, 63.3%) groups. We reviewed clinical characteristics, endoscopic findings, and factors associated with poor outcome-free survival (PFS). Results: In UC patients in CR, PFS was significantly higher in the ER and NRI groups than in the RI group (p=0.003). Patients in the ER and NRI groups had similar PFS (p=0.647). Cox proportional hazard model showed only RI (hazard ratio, 5.76; p=0.027) was associated with a higher risk of poor outcome. Conclusions: We suggest that escalation of treatment modalities may be selectively performed in consideration of the residual mucosal inflammation pattern, even if ER has not been achieved, in UC patients with CR.
Abstract
Background/Aims: The treatment goal of ulcerative colitis (UC) has been changed to achieve endoscopic remission (ER). However, there is insufficient clinical evidence to determine whether a step-up treatment should be performed to achieve ER in clinical remission (CR) without ER, and there are inadequate data on the need to consider the distribution and severity of residual inflammation. This retrospective study aimed to evaluate the prognostic significance of the distribution and severity of residual inflammation in UC patients in CR. Methods: A total of 131 UC patients in CR who underwent endoscopic evaluation for more than three times between January 2000 and December 2018 were reviewed. The patients were allocated by the endoscopic healing state and the distribution of inflammation to ER (n=31, 23.7%), residual nonrectal inflammation with patchy distribution (NRI) (n=17, 13.0%) or residual rectal involvement with continuous or patchy distribution (RI) (n=83, 63.3%) groups. We reviewed clinical characteristics, endoscopic findings, and factors associated with poor outcome-free survival (PFS). Results: In UC patients in CR, PFS was significantly higher in the ER and NRI groups than in the RI group (p=0.003). Patients in the ER and NRI groups had similar PFS (p=0.647). Cox proportional hazard model showed only RI (hazard ratio, 5.76; p=0.027) was associated with a higher risk of poor outcome. Conclusions: We suggest that escalation of treatment modalities may be selectively performed in consideration of the residual mucosal inflammation pattern, even if ER has not been achieved, in UC patients with CR.
참고문헌 (36)
- Ordás I, "Ulcerative colitis", Lancet, 380, pp.1606~1619 (2012)
- 최창환, "궤양성 대장염 진단 가이드라인", 대한소화기학회지, 53(3), pp.145~160 (2009), 대한소화기학회
- D’Haens G, "A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis", Gastroenterology, 132, pp.763~786 (2007)
- Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : determining therapeutic goals for treat-to-target", Am J Gastroenterol, 110, pp.1324~1338 (2015)
- 최창환, "Second Korean guidelines for the management of ulcerative colitis", Intestinal research, 15(1), pp.7~37 (2017), 대한장연구학회
- Neurath MF, "Mucosal healing in inflammatory bowel diseases : a systematic review", Gut, 61, pp.1619~1635 (2012)
- Colombel JF, "Early mucosal healing with infliximab is associated with improved longterm clinical outcomes in ulcerative colitis", Gastroenterology, 141, pp.1194~1201 (2011)
- Vuitton L, "Defining endoscopic response and remission in ulcerative colitis clinical trials : an international consensus", Aliment Pharmacol Ther, 45, pp.801~813 (2017)
- Harbord M, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2 : current management", J Crohns Colitis, 11, pp.769~784 (2017)
- Kleer CG, "Ulcerative colitis : patterns of involvement in colorectal biopsies and changes with time", Am J Surg Pathol, 22, pp.983~989 (1998)
- Bernstein CN, "Patchiness of mucosal inflammation in treated ulcerative colitis : a prospective study", Gastrointest Endosc, 42, pp.232~237 (1995)
- Joo M, "Rectal sparing and skip lesions in ulcerative colitis : a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy", Am J Surg Pathol, 34, pp.689~696 (2010)
- Kim B, "Endoscopic and histological patchiness in treated ulcerative colitis", Am J Gastroenterol, 94, pp.3258~3262 (1999)
- Dignass A, "Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2 : current management", J Crohns Colitis, 6, pp.991~1030 (2012)
- Jauregui-Amezaga A, "Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening", J Crohns Colitis, 7, pp.208~212 (2013)
- Hiroshi Nakase, "Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection: Importance of Controlling Mucosal Inflammation to Prevent Cytomegalovirus Reactivation", Intestinal research, 12(1), pp.5~11 (2014), 대한장연구학회
- Khan N, "Risk of lymphoma in patients with ulcerative colitis treated with thiopurines : a nationwide retrospective cohort study", Gastroenterology, 145, pp.1007~1015 (2013)
- Di Sabatino A, "Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease", Intern Emerg Med, 6(Suppl 1), pp.17~27 (2011)
- Magro F, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1 : definitions, diagnosis, extraintestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders", J Crohns Colitis, 11, pp.649~670 (2017)
- Tysk C, "Ulcerative proctocolitis in Orebro, Sweden : a retrospective epidemiologic study, 1963-1987", Scand J Gastroenterol, 27, pp.945~950 (1992)
- Yang SK, "Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong district, Seoul, Korea, 1986-1997", J Gastroenterol Hepatol, 15, pp.1037~1042 (2000)
- Suzuki Y, "Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation", J Clin Gastroenterol, 49, pp.401~406 (2015)
- Walmsley RS, "A Simple Clinical Colitis Activity Index", Gut, 43, pp.29~32 (1998)
- Simpson SH, "A meta-analysis of the association between adherence to drug therapy and mortality", BMJ, 333, pp.15~ (2006)
- Cramer JA, "Medication compliance and persistence : terminology and definitions", Value Health, 11, pp.44~47 (2008)
- Park SH, "Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare", Can J Gastroenterol Hepatol, 28, pp.125~130 (2014)
- Moum B, "Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time", Am J Gastroenterol, 94, pp.1564~1569 (1999)
- Rajwal SR, "Endoscopic rectal sparing in children with untreated ulcerative colitis", J Pediatr Gastroenterol Nutr, 38, pp.66~69 (2004)
- Anzai H, "Appendiceal orifice inflammation is associated with proximal extension of disease in patients with ulcerative colitis", Colorectal Dis, 18, pp.O278~ (2016)
- Kim B, "Proximal disease extension and related predicting factors in ulcerative proctitis", Scand J Gastroenterol, 49, pp.177~183 (2014)
- Baars JE, "Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation", Inflamm Bowel Dis, 18, pp.1634~1640 (2012)
- Odze R, "Effect of topical 5-aminosalicylic acid(5-ASA)therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis", Am J Surg Pathol, 17, pp.869~875 (1993)
- Rosenberg L, "Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission", Inflamm Bowel Dis, 19, pp.779~784 (2013)
- Fefferman DS, "Endoscopy in inflammatory bowel disease : indications, surveillance, and use in clinical practice", Clin Gastroenterol Hepatol, 3, pp.11~24 (2005)
- Meucci G, "Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine : a prospec-tive, multicenter study", Inflamm Bowel Dis, 18, pp.1006~1010 (2012)
- Nakarai A, "Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse", World J Gastroenterol, 22, pp.5079~5087 (2016)